Table Graph
      published meta-analysis   sensitivity analysis   studies

nitazoxanide in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsSilva, 2021 0.46 [0.03; 8.02] 0.46[0.03; 8.02]Silva, 202110%40NAnot evaluable deathsdetailed resultsRocco, 2020 1.02 [0.02; 51.70] 1.02[0.02; 51.70]Rocco, 202010%392NAnot evaluable clinical deteriorationdetailed resultsRocco, 2020 1.02 [0.29; 3.58] 1.02[0.29; 3.58]Rocco, 202010%392NAnot evaluable clinical improvementdetailed resultsRocco, 2020 0.81 [0.52; 1.27] 0.81[0.52; 1.27]Rocco, 202010%392NAnot evaluable clinical improvement (7-day)detailed resultsRocco, 2020 0.81 [0.52; 1.27] 0.81[0.52; 1.27]Rocco, 202010%392NAnot evaluable ICU admissiondetailed resultsRocco, 2020 4.11 [0.18; 91.83] 4.11[0.18; 91.83]Rocco, 202010%392NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-04-20 04:08 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 633 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons